HF
CVKD icon

HRT Financial’s Cadrenal Therapeutics CVKD Stock Holding History

HRT Financial’s Portfolio CVKD Stock Details CVKD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$97K Buy
+29,055
New +$138K ﹤0.01% 3625

Other funds holding CVKD

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GBT
Grove Bank & Trust Miami, Florida $1.01B AUM 26.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return
Q1WB
Quest 10 Wealth Builders Fuquay-Varina, Virginia $129M AUM 22.73% 1-Year Est. Return

HRT Financial's CVKD Position: Q2 2026 in Review

HRT Financial opened a new position in Cadrenal Therapeutics (CVKD) in Q2 2026: 29,055 shares worth $97K. The stake represents ﹤0.01% of the portfolio and ranks #3625 among its holdings.

20 funds tracked by Wall St. Rank hold CVKD as of Q2 2026.

  • HRT Financial held 29,055 shares of Cadrenal Therapeutics worth $97K as of Q2 2026.
  • Cadrenal Therapeutics was a new HRT Financial position in Q2 2026.
  • Cadrenal Therapeutics made up ﹤0.01% of HRT Financial's portfolio in Q2 2026, its #3625 holding.
  • 20 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.